Effects of genetic variability of CYP2D6 on neural substrates of sustained attention during on-task activity

被引:8
|
作者
Viviani, Roberto [1 ,2 ,3 ]
Messina, Irene [2 ,3 ,4 ]
Bosch, Julia E. [2 ,3 ]
Dommes, Lisa [2 ,3 ]
Paul, Anna [5 ]
Schneider, Katharina L. [5 ]
Scholl, Catharina [5 ]
Stingl, Julia C. [6 ]
机构
[1] Univ Innsbruck, Inst Psychol, Innsbruck, Austria
[2] Univ Ulm, Dept Psychiat, Ulm, Germany
[3] Univ Ulm, Psychotherapy Clin 3, Ulm, Germany
[4] Univ Mercatorum, Rome, Italy
[5] Fed Inst Drugs & Med Devices, Res Div, Bonn, Germany
[6] Univ Hosp RWTH Aachen, Inst Clin Pharmacol, Aachen, Germany
关键词
DRUG-METABOLIZING-ENZYMES; HUMAN BRAIN; CYTOCHROME-P450; ENZYMES; REWARD; ACTIVATION; TIME; POLYMORPHISM; PERFORMANCE; EXPRESSION; DEPENDENCE;
D O I
10.1038/s41398-020-01020-z
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
The polymorphic drug-metabolizing enzyme CYP2D6, which is responsible for the metabolism of most psychoactive compounds, is expressed not only in the liver, but also in the brain. The effects of its marked genetic polymorphism on the individual capacity to metabolize drugs are well known, but its role in metabolism of neural substrates affecting behavior personality or cognition, suggested by its CNS expression, is a long-standing unresolved issue. To verify earlier findings suggesting a potential effect on attentional processes, we collected functional imaging data, while N=415 participants performed a simple task in which the reward for correct responses varied. CYP2D6 allelic variants predicting higher levels of enzymatic activity level were positively associated with cortical activity in occipito-parietal areas as well as in a right lateralized network known to be activated by spatial attentional tasks. Reward-related modulation of activity in cortical areas was more pronounced in poor metabolizers. In conjunction with effects on reaction times, our findings provide evidence for reduced cognitive efficiency in rapid metabolizers compared to poor metabolizers in on-task attentional processes manifested through differential recruitment of a specific neural substrate.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Genetic polymorphism of CYP2D6 in Tamil population
    Abraham, BK
    Adithan, C
    Mohanasundaram, J
    Shashindran, CH
    Koumaravelou, K
    Asad, M
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 56 (11) : 849 - 850
  • [32] Genetic polymorphism of Cyp2d6 in the Greek population
    Ki, A
    Ragia, G
    Kyriaki, S
    Manolopoulos, V
    THERAPEUTIC DRUG MONITORING, 2005, 27 (02) : 234 - 234
  • [33] Genetic polymorphism of CYP2D6 in Tamil population
    Benny K. Abraham
    C. Adithan
    C. H. Shashindran
    K. Koumaravelou
    M. Asad
    J. Mohanasundaram
    European Journal of Clinical Pharmacology, 2001, 56 : 849 - 850
  • [34] Substrate specificity of CYP2D6 genetic variants
    van der Lee, Maaike
    Guchelaar, Henk-Jan
    Swen, Jesse J.
    PHARMACOGENOMICS, 2021, 22 (16) : 1081 - 1089
  • [35] Genetic polymorphisms of CYP2D6 in Chinese mainland
    Ji, L
    Pan, SX
    Wu, JM
    Marti-Jaun, J
    Hersberger, M
    CHINESE MEDICAL JOURNAL, 2002, 115 (12) : 1780 - 1784
  • [36] THE 'ENHANCER' SNP DOES NOT EXPLAIN VARIABILITY OF CYP2D6 ACTIVITY IN VIVO.
    Boone, E. C.
    Staggs, V. T.
    Pearce, R. E.
    Lata, R. F.
    Gaedigk, R.
    Jaime, L. K. Montane
    Cherner, M.
    Berard, A.
    Fridley, B. L.
    Dinh, J. C.
    Miller, N. A.
    Leeder, J.
    Gaedigk, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S57 - S57
  • [37] Variability of the dietary-derived CYP2D6 activity marker solanidine in vivo
    Mueller, J. P.
    Saromba, J.
    Ziegler, P.
    Tremmef', R.
    Rengelshausen, J.
    Schaeffeler, E.
    Just, K. S.
    Schwab, M.
    Kraus, T.
    Sting, J. C.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2024, 397 : S72 - S72
  • [38] CYP2D6 Genotype and Tamoxifen Activity: Understanding Interstudy Variability in Methodological Quality
    Ratain, M. J.
    Nakamura, Y.
    Cox, N. J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 94 (02) : 184 - 186
  • [39] Inter-individual Variability of In Vivo CYP2D6 Activity in Different Genotypes
    Chiba, Koji
    Kato, Motohiro
    Ito, Takashi
    Suwa, Toshio
    Sugiyama, Yuichi
    DRUG METABOLISM AND PHARMACOKINETICS, 2012, 27 (04) : 405 - 413
  • [40] Evaluation of the CYP2D6 Haplotype Activity Scores Based on Metabolic Ratios of 4,700 Patients Treated With Three Different CYP2D6 Substrates
    Jukic, Marin M.
    Smith, Robert L.
    Molden, Espen
    Ingelman-Sundberg, Magnus
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 110 (03) : 750 - 758